| Literature DB >> 29679014 |
Jong Jin Kim1, Bosu Jeong1, Yongin Cho2, Mi-Hyang Kwon2, Yong-Ho Lee2,3,4, Uk Kang1, Eun Seok Kang5,6,7.
Abstract
Skin auto-fluorescence (SAF) has generated broad interest about the prospects for non-invasive advanced glycation end product assessment and its direct interplay with the development of microvascular complications, but clinical application of the existing SAF measuring of non-palmoplantar sites in non-Caucasian subjects with dark skin type is still controversial. Here, we tested the diabetic complication screening performance of a novel SAF measuring system in Asian type 2 diabetes mellitus (T2DM) subjects. A total of 166 Korean patients with T2DM were enrolled in this study and palmoplantar SAF was measured by a newly developed transmission-geometry noninvasive optical system. We found that transmitted SAF values of palmoplantar sites, 1st dorsal interossei muscles of the hand, in a complication group were significantly higher than in a non-complication group while no differences were observed between the two groups in reflected SAF of non-palmoplantar sites. The transmitted SAF values of palmoplantar sites were dramatically increased in subjects with multiple complications and were tightly correlated with the duration of microvascular complications. In conclusion, the SAF measurement in the palmoplantar sites with a non-invasive transmission-geometry optical system provided better microvascular complication screening performance compared to the SAF measurement of non-palmoplantar sites specifically in Asian T2DM subjects.Entities:
Mesh:
Substances:
Year: 2018 PMID: 29679014 PMCID: PMC5910431 DOI: 10.1038/s41598-018-24707-2
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Figure 1Glycated Serum Protein levels and Microvascular Complications. Statistical comparison of HbA1c, GA and GA/HbA1c ratio between a non-complication group and a complication group. Error bars represent standard deviation.
Baseline characteristics of patients according to the complication status.
| Subjects with DM complication (n = 110) | Subjects without DM complication (n = 56) | P value | |
|---|---|---|---|
| Age, years | 60.9 ± 11.5 | 59.3 ± 10.7 | 0.368 |
| Sex, male | 72 (65.5) | 39 (69.6) | 0.588 |
| Body mass index, kg/m2 | 25.4 ± 4.2 | 25.5 ± 4.1 | 0.914 |
| Waist circumference, cm | 89.9 ± 9.6 | 89.1 ± 9.7 | 0.610 |
| SBP, mmHg | 123.7 ± 15.1 | 121.2 ± 12.3 | 0.287 |
| DBP, mmHg | 71.4 ± 9.3 | 73.9 ± 10.8 | 0.121 |
| DM duration, years | 12.7 ± 9.1 | 8.6 ± 6.4 | |
| HbA1c, % | 7.4 ± 1.4 | 7.1 ± 1.2 | 0.218 |
| HbA1c, mmol/mol | 57 ± 16 | 54 ± 13 | 0.218 |
| Glycated Albumin, % | 19.3 ± 5.7 | 17.7 ± 5.0 | 0.107 |
| GA/HbA1c (AU) | 2.4 ± 0.9 | 2.3 ± 0.8 | 0.103 |
| FPG, mg/dL | 134.5 ± 44.2 | 127.2 ± 32.0 | 0.224 |
| Total cholesterol, mg/dL | 158.8 ± 33.9 | 160.5 ± 34.8 | 0.768 |
| HDL-cholesterol, mg/dL | 43.7 ± 10.7 | 45.5 ± 10.9 | 0.144 |
| Triglyceride, mg/dL | 148.7 ± 79.3 | 132.9 ± 57.1 | 0.304 |
| LDL-cholesterol, mg/dL | 85.5 ± 27.4 | 88.4 ± 29.3 | 0.517 |
| UACR (mg/g) | 477.1 ± 1430.0 | 10.5 ± 9.9 | 0.001 |
| eGFR (ml/min/1.73 m2) | 77.0 ± 30.8 | 88.1 ± 19.1 | 0.005 |
| SAF-R (AU) | 2.8 ± 1.1 | 3.0 ± 1.2 | |
| SAF-T (AU) | 6.4 ± 2.5 | 5.1 ± 1.7 | |
| Hypertension | 78 (70.9) | 26 (46.4) | |
| ACEIs or ARBs | 71 (64.5) | 19 (33.9) | |
| CCBs | 39 (35.5) | 17 (30.4) | |
| Beta-blockers | 26 (23.6) | 12 (21.4) | |
| Diuretics | 20 (18.2) | 6 (10.7) | |
| Hyperlipidemia | 86 (78.2) | 35 (62.5) | |
| Statins | 75 (68.2) | 29 (51.8) | |
| Ezetimibe | 15 (13.6) | 3 (5.4) | |
| Fenofibrate | 7 (6.4) | 2 (3.6) | |
| Retinopathy | 60 (36.1) | — | |
| Neuropathy | 39 (23.5) | — | |
| Nephropathy | 69 (41.6) | — |
Data are expressed as the mean ± standard deviation (SD) for continuous variables and percentage (%) for categorical variables. SBP, systolic blood pressure; DBP, diastolic blood pressure; AU, arbitrary unit; FPG, fasting plasma glucose; HDL, high-density lipoprotein; LDL, low-density lipoprotein; UACR, urine albumin-to-creatinine ratio; eGFR, estimated glomerular filtration rate; SAF-R, reflected skin auto-fluorescence on the volar side of the forearms; SAF-T, transmitted skin auto-fluorescence in the 1st interossei muscle of the hand; ACEIs, angiotensin converting enzyme inhibitors; ARBs, angiotensin receptor blockers and CCBs, calcium channel blockers.
Figure 2SAF and Microvascular Complications. (a) Statistical comparison of reflected SAF values on the volar side of the forearms (SAF-R) between a complication group and a non-complication group. (b) Statistical comparison of transmitted SAF values in the 1st dorsal interossei muscles of the hand (SAF-T) between a complication group and a non-complication group. (c) SAF-T values with respect to the number of microvascular complications. (d) SAF-T utilized receiver operating characteristic curves regarding different microvascular complications. Error bars represent standard deviation. (Asterisks *, **, ***, and **** indicate p < 0.05, p < 0.01, p < 0.001, and p < 0.0001, respectively).